Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.
Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Eder JP Jr, et al. Among authors: puchalski ta. J Clin Oncol. 2002 Sep 15;20(18):3772-84. doi: 10.1200/JCO.2002.02.082. J Clin Oncol. 2002. PMID: 12228197 Clinical Trial.
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Eder JP Jr, Ryan DP, Appleman L, Zhu AX, Puchalski T, He X, Sonnichsen DS, Cooper M, Wright J, Clark JW, Supko JG. Eder JP Jr, et al. Cancer Chemother Pharmacol. 2006 Jul;58(1):107-16. doi: 10.1007/s00280-005-0134-0. Epub 2005 Dec 13. Cancer Chemother Pharmacol. 2006. PMID: 16362299 Clinical Trial.
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
Eder JP Jr, Garcia-Carbonero R, Clark JW, Supko JG, Puchalski TA, Ryan DP, Deluca P, Wozniak A, Campbell A, Rothermel J, LoRusso P. Eder JP Jr, et al. Among authors: puchalski ta. Invest New Drugs. 2004 Apr;22(2):139-50. doi: 10.1023/B:DRUG.0000011790.31292.ef. Invest New Drugs. 2004. PMID: 14739662 Clinical Trial.
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD. Garcia-Carbonero R, et al. Among authors: puchalski ta. J Clin Oncol. 2004 Apr 15;22(8):1480-90. doi: 10.1200/JCO.2004.02.098. J Clin Oncol. 2004. PMID: 15084621 Clinical Trial.
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD. Garcia-Carbonero R, et al. Among authors: puchalski ta. J Clin Oncol. 2005 Aug 20;23(24):5484-92. doi: 10.1200/JCO.2005.05.028. J Clin Oncol. 2005. PMID: 16110008 Clinical Trial.
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG. Puchalski TA, et al. Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19. doi: 10.1007/s00280-002-0498-3. Epub 2002 Jul 31. Cancer Chemother Pharmacol. 2002. PMID: 12357306 Clinical Trial.
40 results